Odyssey Therapeutics

Autoimmune diseases biotech Odyssey Therapeutics refiles for a $100 million IPO May 8, 2026 News Autoimmune diseases biotech Odyssey Therapeutics prices upsized IPO at $18, the high end of the range Odyssey Therapeutics, a Phase 2 biotech developing precision therapies... Read more